Compare Asana Inc. (ASAN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asana Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Asana Inc. trades at $9.25 (market cap $2.13B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 39.1× Asana Inc.'s market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Asana Inc. pays none. Which is the better fit depends on your goals.
| ASAN | REGN | |
|---|---|---|
Market Cap | $2.13B | $83.19B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.19 | $812.27 |
52-Week Low | $5.46 | $555.51 |
Enterprise Value | $1.95B | $77.90B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $9.26, up 6.68% today, with a bullish technical signal from moving averages and a consensus price target of $10.33. Recent quarterly earnings have consistently beaten expectations, including Q1 2027 EPS of $0.10 versus $0.08 expected. Revenue growth is steady, reaching $724 million in 2025, but profitability remains negative with a net margin of -20.21%. The company is advancing its AI capabilities, highlighted by the StackAI acquisition announced on May 28, 2026.
The outlook is mixed: strong revenue growth and AI innovation support upside potential, but persistent losses and intense competition from Microsoft and Alphabet pose significant risks. Analyst sentiment is divided, with 42% buy ratings. Earnings momentum is key for sustained gains.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
